Therapeutics that enhance the protease activity of tissue plasminogen activator, furin, plasmin, and MMPs, which convert proBDNF to mature BDNF, may aid in treating neurodegenerative disorders, including Alzheimer’s disease [126]. This evidence concerns the gene PLG and Alzheimer disease.